NervGen Pharma ernennt Adam Rogers zum CEO
I'm PortAI, I can summarize articles.
NervGen Pharma Corp. has appointed Adam Rogers, MD, as the new President and Chief Executive Officer, effective immediately. Rogers will lead the company in advancing its main product NVG-291 and will be responsible for the strategic direction in therapies for spinal cord injuries.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments